Workflow
医药新零售服务
icon
Search documents
益丰药房(603939):2025年中报点评:区域聚焦降本增效
Dongguan Securities· 2025-08-29 06:50
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [1][6]. Core Views - The company reported a total revenue of 11.722 billion yuan for the first half of 2025, a slight decrease of 0.34% year-on-year, while the net profit attributable to shareholders increased by 10.32% year-on-year to 880 million yuan, aligning with expectations [1]. - The decline in revenue is attributed to the closure of some stores and a slowdown in new store expansion, while the increase in net profit is due to cost reduction and efficiency improvements [3]. - The company aims to consolidate its presence in Central South, East China, and North China while expanding nationally, with a focus on a multi-tiered store network [3]. - The company has continued to develop its online business, achieving a total sales revenue of 1.355 billion yuan from internet operations in the first half of 2025, with O2O sales contributing 944 million yuan and B2C sales contributing 411 million yuan [3]. - The gross margin improved by 0.42 percentage points to 40.47%, and the net profit margin increased by 0.76 percentage points to 8.07%, benefiting from cost reduction and efficiency improvements [3]. Summary by Sections Financial Performance - For the first half of 2025, the company achieved total revenue of 11.722 billion yuan and a net profit of 880 million yuan, with respective year-on-year changes of -0.34% and +10.32% [1]. - The company’s total number of stores reached 14,701, including 10,681 direct-operated stores and 4,020 franchise stores [3]. Future Projections - The company forecasts earnings per share of 1.45 yuan and 1.69 yuan for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 17 times and 14 times, indicating that the current valuation is at a historical low for the past decade [3][4].